Impact of resection margin on outcomes in high-grade soft tissue sarcomas of the extremity-A USSC analysis.
R resection status
high-grade extremity sarcomas
negative margins
predictors of recurrence
Journal
Journal of surgical oncology
ISSN: 1096-9098
Titre abrégé: J Surg Oncol
Pays: United States
ID NLM: 0222643
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
12
08
2020
revised:
26
09
2020
accepted:
12
10
2020
pubmed:
6
11
2020
medline:
5
3
2021
entrez:
5
11
2020
Statut:
ppublish
Résumé
The optimal margin of resection for high-grade extremity sarcomas and its impact on survival has long been questioned in the setting of adjuvant radiotherapy. The objective of this study was to investigate the impact of resection status on recurrence and survival. All patients with primary, nonmetastatic, high-grade extremity sarcomas that underwent surgical resection from January 2000 to April 2016 in the U.S. Sarcoma Collaborative (USSC) were retrospectively reviewed. Recurrence patterns, recurrence-free survival (RFS), and overall survival (OS) were examined in multivariate analyses (MVA). A cohort of 959 patients was identified with a median follow-up of 34.7 months from diagnosis. R0 resection was achieved in 86.7% (831) while R1 resection in 13.3% (128). Locoregional recurrence for R0 and R1 groups occurred in 9.1% (76) versus 14.8% (19; p = .05) while distant recurrence occurred in 24.7% (205) versus 26.6% (34; p = .65), respectively. Median RFS was 171.2 versus 48.5 (p = .01) while median OS was 149.8 versus 71.5 months (p = .02) for the R0 versus R1 group, respectively. On MVA, female gender (hazard ratio [HR] = 0.69, p = .007) and adjuvant radiotherapy (0.7, p = .04) were associated with improved OS, whereas older age (HR = 1.03, p < .001) and tumor size (HR = 1.01, p < .001) were associated with worse OS. R0 resection status was associated with improved locoregional RFS (HR = 0.56, p = .03) but not with distant RFS (HR = 0.84, p = .4) or OS (HR = 0.7, p = .052). In high-grade extremity sarcomas, tumor size and gender are predictive of OS while R0 resection status is associated with improved locoregional recurrence rate without a significant impact on distant RFS or OS.
Sections du résumé
BACKGROUND
BACKGROUND
The optimal margin of resection for high-grade extremity sarcomas and its impact on survival has long been questioned in the setting of adjuvant radiotherapy. The objective of this study was to investigate the impact of resection status on recurrence and survival.
METHODS
METHODS
All patients with primary, nonmetastatic, high-grade extremity sarcomas that underwent surgical resection from January 2000 to April 2016 in the U.S. Sarcoma Collaborative (USSC) were retrospectively reviewed. Recurrence patterns, recurrence-free survival (RFS), and overall survival (OS) were examined in multivariate analyses (MVA).
RESULTS
RESULTS
A cohort of 959 patients was identified with a median follow-up of 34.7 months from diagnosis. R0 resection was achieved in 86.7% (831) while R1 resection in 13.3% (128). Locoregional recurrence for R0 and R1 groups occurred in 9.1% (76) versus 14.8% (19; p = .05) while distant recurrence occurred in 24.7% (205) versus 26.6% (34; p = .65), respectively. Median RFS was 171.2 versus 48.5 (p = .01) while median OS was 149.8 versus 71.5 months (p = .02) for the R0 versus R1 group, respectively. On MVA, female gender (hazard ratio [HR] = 0.69, p = .007) and adjuvant radiotherapy (0.7, p = .04) were associated with improved OS, whereas older age (HR = 1.03, p < .001) and tumor size (HR = 1.01, p < .001) were associated with worse OS. R0 resection status was associated with improved locoregional RFS (HR = 0.56, p = .03) but not with distant RFS (HR = 0.84, p = .4) or OS (HR = 0.7, p = .052).
CONCLUSIONS
CONCLUSIONS
In high-grade extremity sarcomas, tumor size and gender are predictive of OS while R0 resection status is associated with improved locoregional recurrence rate without a significant impact on distant RFS or OS.
Identifiants
pubmed: 33150594
doi: 10.1002/jso.26275
pmc: PMC9716343
mid: NIHMS1842197
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
479-488Subventions
Organisme : NCI NIH HHS
ID : P30 CA012197
Pays : United States
Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Ann Surg Oncol. 2018 Mar;25(3):754-767
pubmed: 28895107
Ann Surg. 2010 Mar;251(3):506-11
pubmed: 20130465
J Surg Res. 2020 Dec;256:492-501
pubmed: 32798997
Cancer. 2003 May 15;97(10):2544-53
pubmed: 12733154
Ann Surg Oncol. 2017 Jan;24(1):194-201
pubmed: 27491785
J Clin Oncol. 2018 Mar 1;36(7):704-709
pubmed: 29346043
Cancer. 1981 May 15;47(10):2391-7
pubmed: 7272893
Surg Clin North Am. 2016 Oct;96(5):915-62
pubmed: 27542635
Ann Surg. 1982 Sep;196(3):305-15
pubmed: 7114936
Radiology. 2019 Jun;291(3):710-721
pubmed: 30964422
J Natl Compr Canc Netw. 2018 May;16(5):536-563
pubmed: 29752328
J Clin Oncol. 1996 May;14(5):1679-89
pubmed: 8622088
Nat Rev Cancer. 2003 Sep;3(9):685-94
pubmed: 12951587
Ann Surg. 1975 Nov;182(5):597-602
pubmed: 1190864
J Clin Oncol. 1998 Jan;16(1):197-203
pubmed: 9440743
Arch Surg. 1981 Jun;116(6):765-9
pubmed: 7235973
J Clin Oncol. 1996 Mar;14(3):859-68
pubmed: 8622034
Cancer. 2003 May 15;97(10):2530-43
pubmed: 12733153
Arch Pathol Lab Med. 2006 Oct;130(10):1448-53
pubmed: 17090186